APA aipamena

Smolen, J. S., Choe, J., Prodanovic, N., Niebrzydowski, J., Staykov, I., Dokoupilova, E., . . . Rho, Y. H. (2017). Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: Clinical, structural and safety results. Rheumatology (Oxford).

Chicago Style aipamena

Smolen, Josef S., et al. "Comparing Biosimilar SB2 With Reference Infliximab After 54 Weeks of a Double-blind Trial: Clinical, Structural and Safety Results." Rheumatology (Oxford) 2017.

MLA aipamena

Smolen, Josef S., et al. "Comparing Biosimilar SB2 With Reference Infliximab After 54 Weeks of a Double-blind Trial: Clinical, Structural and Safety Results." Rheumatology (Oxford) 2017.